Nakhlis Faina, Gilmore Lauren, Gelman Rebecca, Bedrosian Isabelle, Ludwig Kandice, Hwang E Shelley, Willey Shawna, Hudis Clifford, Iglehart J Dirk, Lawler Elizabeth, Ryabin Nicole Y, Golshan Mehra, Schnitt Stuart J, King Tari A
Dana-Farber/Harvard Cancer Center, Boston, MA, USA.
Dana-Farber/Brigham and Women's Cancer Center, Boston, MA, USA.
Ann Surg Oncol. 2016 Mar;23(3):722-8. doi: 10.1245/s10434-015-4922-4. Epub 2015 Nov 5.
Lobular neoplasia (LN) represents a spectrum of atypical proliferative lesions, including atypical lobular hyperplasia and lobular carcinoma-in-situ. The need for excision for LN found on core biopsy (CB) is controversial. We conducted a prospective multi-institutional trial (TBCRC 20) to determine the rate of upgrade to cancer after excision for pure LN on CB.
Patients with a CB diagnosis of pure LN were prospectively identified and consented to excision. Cases with discordant imaging and those with additional lesions requiring excision were excluded. Upgrade rates to cancer were quantified on the basis of local and central pathology review. Confidence intervals and sample size were based on exact binomial calculations.
A total of 77 of 79 registered patients underwent excision (median age 51 years, range 27-82 years). Two cases (3%; 95% confidence interval 0.3-9) were upgraded to cancer (one tubular carcinoma, one ductal carcinoma-in-situ) at excision per local pathology. Central pathology review of 76 cases confirmed pure LN in the CB in all but two cases. In one case, the tubular carcinoma identified at excision was also found in the CB specimen, and in the other, LN was not identified, yielding an upgrade rate of one case (1%; 95% CI 0.01-7) by central pathology review.
In this prospective study of 77 patients with pure LN on CB, the upgrade rate was 3% by local pathology and 1% by central pathology review, demonstrating that routine excision is not indicated for patients with pure LN on CB and concordant imaging findings.
小叶瘤变(LN)代表一系列非典型增生性病变,包括非典型小叶增生和小叶原位癌。对于在粗针活检(CB)中发现的LN是否需要切除存在争议。我们进行了一项前瞻性多机构试验(TBCRC 20),以确定CB诊断为单纯LN的患者切除术后癌症升级的发生率。
前瞻性识别出CB诊断为单纯LN的患者并同意进行切除。排除影像学结果不一致的病例以及有其他需要切除病变的病例。根据局部和中心病理检查结果对癌症升级率进行量化。置信区间和样本量基于精确二项式计算。
79例登记患者中有77例接受了切除(中位年龄51岁,范围27 - 82岁)。根据局部病理检查,有2例(3%;95%置信区间0.3 - 9)在切除时升级为癌症(1例管状癌,1例导管原位癌)。对76例病例的中心病理检查证实,除2例以外,CB中的病变均为单纯LN。1例中,切除时发现的管状癌在CB标本中也被发现,另1例未发现LN,经中心病理检查,升级率为1例(1%;95%CI 0.01 - 7)。
在这项对77例CB诊断为单纯LN的患者的前瞻性研究中,局部病理检查的升级率为3%,中心病理检查为1%,表明对于CB诊断为单纯LN且影像学结果一致的患者,不建议进行常规切除。